New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Global ETF Survey 2026
XDWH

Xtrackers MSCI World Health Care UCITS ETF

The XDWH Exchange Traded Fund (ETF) is provided by Xtrackers by DWS. It is built to track an index: MSCI World Health Care Index. The XDWH ETF provides physical exposure, so by buying it you actually own parts of all the 113 underlying holdings. The dividend policy is capitalization.

Advertisement

Advertisement

API
PerformanceDec 31, 2025 - Jul 24, 2026
-6%-4%-2%0%2%4%6%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 06/30/26
Healthcare
97.49%
Consumer Non-Cyclicals
1.63%
Other
0.82%
Latest XDWH news

FAQ about XDWH

XDWH is a Passive ETF. This ETF provides exposure to Large and Mid-Cap Developed markets Health Care Equities.
XDWH tracks the MSCI Daily Total Return World Net Health Care Index - USD, through a full replication replication method.
XDWH carries a total expense ratio (TER) of 0.25%, indicating the annual cost for holding the fund.
XDWH was introduced to the market on March 4, 2016. It trades on Austria, among other exchanges
Xtrackers MSCI World Health Care UCITS ETF, XDWH, is provided by Xtrackers by DWS. Learn more about Xtrackers by DWS here.
XDWH oversees €3.26B in assets as of July 24, 2026.
XDWH follows a capitalizing, meaning it reinvests income within the fund.
As of June 30, 2026, XDWH has significant geographic allocations in USA, Switzerland and United Kingdom.
As of June 30, 2026, XDWH focuses largely on Healthcare and Consumer Non-Cyclicals.
As of June 30, 2026, XDWH holds 113 positions in its portfolio, with 58.27% of assets concentrated in its top 15 holdings.
As of June 30, 2026, XDWH top three holdings include Eli Lilly & Co., Johnson & Johnson and AbbVie, Inc..
The base currency of XDWH is USD.
Data as of 06/30/26
Eli Lilly & Co.
11.91%
Johnson & Johnson
7.53%
AbbVie, Inc.
5.50%
UnitedHealth Group, Inc.
4.77%
Merck & Co., Inc.
3.91%
Roche Holding AG
3.58%
Novartis AG
3.51%
AstraZeneca PLC
3.51%
Amgen, Inc.
2.37%
Thermo Fisher Scientific, Inc.
2.34%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight